SCHEMBL5147979

SCHEMBL5147979

CCn1nc(-c2ncc(NCc3ccc(OC)cc3)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.43
HIF1A Q16665 1/20 0.43
AXL P30530 1/20 0.42
TYRO3 Q06418 1/20 0.42
MERTK Q12866 1/20 0.42
MAPK13 O15264 1/20 0.42
RAF1 P04049 1/20 0.42
MAPK9 P45984 1/20 0.42
MAPK12 P53778 1/20 0.42
MAPK11 Q15759 1/20 0.42
MAPK14 Q16539 1/20 0.42
HRH1 P35367 1/20 0.42
HRH4 Q9H3N8 1/20 0.42
CLK4 Q9HAZ1 3/20 0.41
DYRK1A Q13627 2/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HDAC1 Q13547 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5150680 0.86 GAA (0.45) GAAHIF1AMAPK13RAF1MAPK9
SCHEMBL5149215 0.83 GAA (0.45) GAAHIF1AMAPK13RAF1MAPK9
SCHEMBL5149098 0.82 HIF1A (0.44) HIF1AMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL5149125 0.80 ALDH1A1 (0.46) GAAHIF1AMAPK13RAF1MAPK9
SCHEMBL5147930 0.74 ADORA2A (0.43) SMN1; SMN2MEN1KMT2AHDAC1HTT
SCHEMBL27659527 0.71 HTT (0.47) SMN1; SMN2MEN1KMT2AHTT
SCHEMBL5148003 0.71 HIF1A (0.46) GAAHIF1AMAPK13RAF1MAPK9
SCHEMBL28700972 0.70 CYP1A2 (0.50) GAAHIF1AMAPK14CLK4MAPT
SCHEMBL30725768 0.70 CYP1A2 (0.50) GAAHIF1AMAPK14CLK4MAPT
SCHEMBL3841611 0.69 MAPT (0.70) MAPTSMN1; SMN2MEN1KMT2AHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
CN-1938296-A Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists ASTELLAS PHARMA INC (JP) 2007-03-28 CN disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 GAA 1578/4885HIF1A 416/4885AXL 3325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.